Single versus multiple reoperations for recurrent intracranial meningiomas.
Extent of resection
Intracranial meningioma
Ki67-MIB1
Multiple recurrences
Time to recurrence
WHO grade
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
24 Apr 2024
24 Apr 2024
Historique:
received:
06
03
2024
accepted:
01
04
2024
medline:
24
4
2024
pubmed:
24
4
2024
entrez:
24
4
2024
Statut:
aheadofprint
Résumé
To identify the risk factors and management of the multiple recurrences and reoperations for intracranial meningiomas. Data of a neurosurgical series of 35 patients reoperated on for recurrent intracranial meningiomas were reviewed. Analyzed factors include patient age and sex, tumor location, extent of resection, WHO grade, Ki67-MIB1 and PR expression at initial diagnosis, time to recurrence; pattern of regrowth, extent of resection, WHO grade and Ki67-MIB1 at first recurrence were also analyzed. All these factors were stratified into two groups based on single (Group A) and multiple reoperations (Group B). Twenty-four patients (69%) belonged to group A and 11 (31%) to group B. The age < 65 years, male sex, incomplete resection at both initial surgery and first reoperation, and multicentric-diffuse pattern of regrowth at first recurrence are risk factors for multiple recurrences and reoperations. In group B, the WHO grade and Ki67-MIB1 increased in further recurrences in 54% and 64%, respectively. The time to recurrence was short in 7 cases (64%), whereas 4 patients (36%) further recurred after many years. Eight patients (73%) are still alive after 7 to 22 years and 2 to 4 reoperations. The extent of resection and the multicentric-diffuse pattern of regrowth at first recurrence are the main risk factors for multiple recurrences and reoperations. Repeated reoperations might be considered even in patients with extensive recurrent tumors before the anaplastic transformation occurs. In such cases, even partial tumor resections followed by radiation therapy may allow long survival in good clinical conditions.
Identifiants
pubmed: 38656725
doi: 10.1007/s11060-024-04673-8
pii: 10.1007/s11060-024-04673-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Aghi MK, Carter BS, Cosgrove GR, Ojemann RG, Amin-Hanjani S, Martuza RL, Curry WT, Barker FG (2009) Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery 64:56–60 discussion 60. https://doi.org/10.1227/01.NEU.0000330399.55586.63
doi: 10.1227/01.NEU.0000330399.55586.63
pubmed: 19145156
Nakasu S, Fukami T, Jito J, Nozaki K (2009) Recurrence and regrowth of benign meningiomas. Brain Tumor Pathol 26:69–72. https://doi.org/10.1007/s10014-009-0251-2
doi: 10.1007/s10014-009-0251-2
pubmed: 19856217
Matsuno A, Fujimaki T, Sasaki T, Nagashima T, Ide T, Asai A, Matsuura R, Utsunomiya H, Kirino T (1996) Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas. Acta Neuropathol 91:504–510
doi: 10.1007/s004010050458
pubmed: 8740231
Maiuri F, De Caro MB, Esposito F, Cappabianca P, Strazzullo V, Pettinato G, de Divitiis E (2007) Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors. J Neurooncol 82:63–68. https://doi.org/10.1007/s11060-005-9078-9
doi: 10.1007/s11060-005-9078-9
pubmed: 17225937
Franca RA, Della Monica R, Corvino S, Chiariotti L, Del Caro B M (2023) WHO grade and pathological markers of meningiomas: clinical and prognostic role. Pathol Res Pract 243:154340. https://doi.org/10.1016/j.prp.2023.154340
doi: 10.1016/j.prp.2023.154340
pubmed: 36738518
Oya S, Kawai K, Nakatomi H, Saito N (2012) Significance of Simpson grading system in modern meningioma surgery: integration of the grade with MIB-1 labeling index as a key to predict the recurrence of WHO Grade I meningiomas. J Neurosurg 117:121–128. https://doi.org/10.3171/2012.3.JNS111945
doi: 10.3171/2012.3.JNS111945
pubmed: 22559847
Liu N, Song SY, Jiang JB, Wang TJ, Yan CX (2020) The prognostic role of Ki-67/MIB-1 in meningioma: a systematic review with meta-analysis. Med (Baltim) 99:e18644. https://doi.org/10.1097/MD.0000000000018644
doi: 10.1097/MD.0000000000018644
Mirian C, Skyrman S, Bartek J, Jensen LR, Kihlström L, Förander P, Orrego A, Mathiesen T (2020) The Ki-67 Proliferation Index as a marker of time to recurrence in Intracranial Meningioma. Neurosurgery 87:1289–1298. https://doi.org/10.1093/neuros/nyaa226
doi: 10.1093/neuros/nyaa226
pubmed: 32614441
Olar A, Wani KM, Sulman EP, Mansouri A, Zadeh G, Wilson CD, DeMonte F, Fuller GN, Aldape KD (2015) Mitotic index is an independent predictor of recurrence-free survival in Meningioma. Brain Pathol 25:266–275. https://doi.org/10.1111/bpa.12174
doi: 10.1111/bpa.12174
pubmed: 25040885
SIMPSON D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20:22–39
doi: 10.1136/jnnp.20.1.22
pubmed: 13406590
pmcid: 497230
Hwang WL, Marciscano AE, Niemierko A, Kim DW, Stemmer-Rachamimov AO, Curry WT, Barker FG, Martuza RL, Loeffler JS, Oh KS, Shih HA, Larvie M (2016) Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade. Neuro Oncol 18:863–872. https://doi.org/10.1093/neuonc/nov285
doi: 10.1093/neuonc/nov285
pubmed: 26597949
Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, Schiff D, Weber DC, Wen PY, Vogelbaum MA (2015) Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 122:4–23. https://doi.org/10.3171/2014.7.JNS131644
doi: 10.3171/2014.7.JNS131644
pubmed: 25343186
pmcid: 5062955
Sun SQ, Kim AH, Cai C, Murphy RK, DeWees T, Sylvester P, Dacey RG, Grubb RL, Rich KM, Zipfel GJ, Dowling JL, Leuthardt EC, Leonard JR, Evans J, Simpson JR, Robinson CG, Perrin RJ, Huang J, Chicoine MR (2014) Management of atypical cranial meningiomas, part 1: predictors of recurrence and the role of adjuvant radiation after gross total resection. Neurosurgery 75:347–354 discussion 354– 345; quiz 355. https://doi.org/10.1227/NEU.0000000000000461
doi: 10.1227/NEU.0000000000000461
pubmed: 24932707
Domingues PH, Sousa P, Otero Á, Gonçalves JM, Ruiz L, de Oliveira C, Lopes MC, Orfao A, Tabernero MD (2014) Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype. Neuro Oncol 16:735–747. https://doi.org/10.1093/neuonc/not325
doi: 10.1093/neuonc/not325
pubmed: 24536048
pmcid: 3984558
Maiuri F, Corvino S, Lorenzetti M, Franca RA, Esposito F, Del Caro B M (2023) Intracranial meningiomas in patients aged ≥ 80 years: pathological features and Surgical problems. World Neurosurg 173:e498–e508. https://doi.org/10.1016/j.wneu.2023.02.086
doi: 10.1016/j.wneu.2023.02.086
pubmed: 36841531
Magill ST, Young JS, Chae R, Aghi MK, Theodosopoulos PV, McDermott MW (2018) Relationship between tumor location, size, and WHO grade in meningioma. Neurosurg Focus 44:E4. https://doi.org/10.3171/2018.1.FOCUS17752
doi: 10.3171/2018.1.FOCUS17752
pubmed: 29606048
Nakasu S, Nakasu Y, Nakajima M, Matsuda M, Handa J (1999) Preoperative identification of meningiomas that are highly likely to recur. J Neurosurg 90:455–462. https://doi.org/10.3171/jns.1999.90.3.0455
doi: 10.3171/jns.1999.90.3.0455
pubmed: 10067913
McGovern SL, Aldape KD, Munsell MF, Mahajan A, DeMonte F, Woo SY (2010) A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. J Neurosurg 112:925–933. https://doi.org/10.3171/2009.9.JNS09617
doi: 10.3171/2009.9.JNS09617
pubmed: 19799498
Maiuri F, Mariniello G, Guadagno E, Barbato M, Corvino S, Del Basso De Caro M (2019) WHO grade, proliferation index, and progesterone receptor expression are different according to the location of meningioma. Acta Neurochir (Wien) 161:2553–2561. https://doi.org/10.1007/s00701-019-04084-z
doi: 10.1007/s00701-019-04084-z
pubmed: 31637512
Maiuri F, Corvino S (2023) Meningiomas of the rolandic region: risk factors for motor deficit and role of intra-operative monitoring. Acta Neurochir (Wien) 165:1707–1716. https://doi.org/10.1007/s00701-023-05630-6
doi: 10.1007/s00701-023-05630-6
pubmed: 37277557
Maiuri F, Mariniello G, Barbato M, Corvino S, Guadagno E, Chiariotti L, Del Caro B M (2022) Malignant intraventricular meningioma: literature review and case report. Neurosurg Rev 45:151–166. https://doi.org/10.1007/s10143-021-01585-3
doi: 10.1007/s10143-021-01585-3
pubmed: 34159472
Nawashiro H (2000) Tumor shape and recurrence. J Neurosurg 93:528
pubmed: 10969963
Fewings PE, Battersby RD, Timperley WR (2000) Long-term follow up of progesterone receptor status in benign meningioma: a prognostic indicator of recurrence? J Neurosurg 92:401–405. https://doi.org/10.3171/jns.2000.92.3.0401
doi: 10.3171/jns.2000.92.3.0401
pubmed: 10701525
Roser F, Nakamura M, Bellinzona M, Rosahl SK, Ostertag H, Samii M (2004) The prognostic value of progesterone receptor status in meningiomas. J Clin Pathol 57:1033–1037. https://doi.org/10.1136/jcp.2004.018333
doi: 10.1136/jcp.2004.018333
pubmed: 15452155
pmcid: 1770447
Pravdenkova S, Al-Mefty O, Sawyer J, Husain M (2006) Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. J Neurosurg 105:163–173. https://doi.org/10.3171/jns.2006.105.2.163
doi: 10.3171/jns.2006.105.2.163
pubmed: 17219818
Maiuri F, Mariniello G, de Divitiis O, Esposito F, Guadagno E, Teodonno G, Barbato M, Del Caro B M (2021) Progesterone receptor expression in Meningiomas: pathological and prognostic implications. Front Oncol 11:611218. https://doi.org/10.3389/fonc.2021.611218
doi: 10.3389/fonc.2021.611218
pubmed: 34336636
pmcid: 8320886
Goldbrunner R, Stavrinou P, Jenkinson MD, Sahm F, Mawrin C, Weber DC, Preusser M, Minniti G, Lund-Johansen M, Lefranc F, Houdart E, Sallabanda K, Le Rhun E, Nieuwenhuizen D, Tabatabai G, Soffietti R, Weller M (2021) EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol 23:1821–1834. https://doi.org/10.1093/neuonc/noab150
doi: 10.1093/neuonc/noab150
pubmed: 34181733
pmcid: 8563316
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106
doi: 10.1093/neuonc/noab106
pubmed: 34185076
pmcid: 8328013
Maiuri F, Corvino S, Guadagno E, Del Caro B (2021) M Topographic distribution of intracranial meningioma’s recurrences: localized versus diffuse-multicentric. [Internet]. Frontiers in Clinical Neurosurgery. IntechOpen; 2021. https://doi.org/10.5772/intechopen.97120
Maiuri F, Mariniello G, Peca C, Guadagno E, Corvino S, d’Avanzo S, Del Caro B, de Divitiis M O (2020) Multicentric and diffuse recurrences of meningiomas. Br J Neurosurg 1–8. https://doi.org/10.1080/02688697.2020.1754335
Mansouri A, Klironomos G, Taslimi S, Kilian A, Gentili F, Khan OH, Aldape K, Zadeh G (2016) Surgically resected skull base meningiomas demonstrate a divergent postoperative recurrence pattern compared with non-skull base meningiomas. J Neurosurg 125:431–440. https://doi.org/10.3171/2015.7.JNS15546
doi: 10.3171/2015.7.JNS15546
pubmed: 26722844
Savardekar AR, Patra DP, Bir S, Thakur JD, Mohammed N, Bollam P, Georgescu MM, Nanda A (2018) Differential Tumor progression patterns in Skull Base Versus Non-skull Base meningiomas: a critical analysis from a long-term Follow-Up study and review of literature. World Neurosurg 112:e74–e83. https://doi.org/10.1016/j.wneu.2017.12.035
doi: 10.1016/j.wneu.2017.12.035
pubmed: 29258946
Materi J, Mampre D, Ehresman J, Rincon-Torroella J, Chaichana KL (2020) Predictors of recurrence and high growth rate of residual meningiomas after subtotal resection. J Neurosurg 134:410–416. https://doi.org/10.3171/2019.10.JNS192466
doi: 10.3171/2019.10.JNS192466
pubmed: 31899874
Sandalcioglu IE, Gasser T, Mohr C, Stolke D, Wiedemayer H (2005) Spheno-orbital meningiomas: interdisciplinary surgical approach, resectability and long-term results. J Craniomaxillofac Surg 33:260–266. https://doi.org/10.1016/j.jcms.2005.01.013
doi: 10.1016/j.jcms.2005.01.013
pubmed: 15978821
Mariniello G, de Divitiis O, Corvino S, Strianese D, Iuliano A, Bonavolontà G, Maiuri F (2022) Recurrences of Spheno-Orbital meningiomas: risk factors and management. World Neurosurg. https://doi.org/10.1016/j.wneu.2022.02.048
doi: 10.1016/j.wneu.2022.02.048
pubmed: 35231620
Nanda A, Vannemreddy P (2008) Recurrence and outcome in skull base meningiomas: do they differ from other intracranial meningiomas? Skull Base 18:243–252. https://doi.org/10.1055/s-2007-1016956
doi: 10.1055/s-2007-1016956
pubmed: 19119339
pmcid: 2467481
Lam Shin Cheung V, Kim A, Sahgal A, Das S (2018) Meningioma recurrence rates following treatment: a systematic analysis. J Neurooncol 136:351–361. https://doi.org/10.1007/s11060-017-2659-6
doi: 10.1007/s11060-017-2659-6
pubmed: 29143273
Bi WL, Abedalthagafi M, Horowitz P, Agarwalla PK, Mei Y, Aizer AA, Brewster R, Dunn GP, Al-Mefty O, Alexander BM, Santagata S, Beroukhim R, Dunn IF (2016) Genomic landscape of intracranial meningiomas. J Neurosurg 125:525–535. https://doi.org/10.3171/2015.6.JNS15591
doi: 10.3171/2015.6.JNS15591
pubmed: 26771848
Boetto J, Peyre M, Kalamarides M (2021) Meningiomas from a developmental perspective: exploring the crossroads between meningeal embryology and tumorigenesis. Acta Neurochir (Wien) 163:57–66. https://doi.org/10.1007/s00701-020-04650-w
doi: 10.1007/s00701-020-04650-w
pubmed: 33216210
Okano A, Miyawaki S, Hongo H, Dofuku S, Teranishi Y, Mitsui J, Tanaka M, Shin M, Nakatomi H, Saito N (2021) Associations of pathological diagnosis and genetic abnormalities in meningiomas with the embryological origins of the meninges. Sci Rep 11:6987. https://doi.org/10.1038/s41598-021-86298-9
doi: 10.1038/s41598-021-86298-9
pubmed: 33772057
pmcid: 7998008
Gousias K, Schramm J, Simon M (2016) The Simpson grading revisited: aggressive surgery and its place in modern meningioma management. J Neurosurg 125:551–560. https://doi.org/10.3171/2015.9.JNS15754
doi: 10.3171/2015.9.JNS15754
pubmed: 26824369
Magill ST, Dalle Ore CL, Diaz MA, Jalili DD, Raleigh DR, Aghi MK, Theodosopoulos PV, McDermott MW (2018) Surgical outcomes after reoperation for recurrent non-skull base meningiomas. J Neurosurg 1–9. https://doi.org/10.3171/2018.6.JNS18118
Magill ST, Lee DS, Yen AJ, Lucas CG, Raleigh DR, Aghi MK, Theodosopoulos PV, McDermott MW (2018) Surgical outcomes after reoperation for recurrent skull base meningiomas. J Neurosurg 130:876–883. https://doi.org/10.3171/2017.11.JNS172278
doi: 10.3171/2017.11.JNS172278
pubmed: 29726777
Lemée JM, Corniola MV, Meling TR (2020) Benefits of re-do surgery for recurrent intracranial meningiomas. Sci Rep 10:303. https://doi.org/10.1038/s41598-019-57254-5
doi: 10.1038/s41598-019-57254-5
pubmed: 31941981
pmcid: 6962359
Strik HM, Strobelt I, Pietsch-Breitfeld B, Iglesias-Rozas JR, Will B, Meyermann R (2002) The impact of progesterone receptor expression on relapse in the long-term clinical course of 93 benign meningiomas. Vivo 16:265–270
Borovich B, Doron Y (1986) Recurrence of intracranial meningiomas: the role played by regional multicentricity. J Neurosurg 64:58–63. https://doi.org/10.3171/jns.1986.64.1.0058
doi: 10.3171/jns.1986.64.1.0058
pubmed: 3941351
Kinjo T, al-Mefty O, Kanaan I (1993) Grade zero removal of supratentorial convexity meningiomas. Neurosurgery 33:394–399 discussion 399. https://doi.org/10.1227/00006123-199309000-00007
doi: 10.1227/00006123-199309000-00007
pubmed: 8413869
Obiri-Yeboah D, Soni P, Oyem PC, Almeida JP, Murayi R, Recinos PF, Kshettry VR (2023) Beyond the Surgical Margin: patterns of recurrence in World Health Organization Grade 2 intracranial meningiomas. World Neurosurg. https://doi.org/10.1016/j.wneu.2023.06.100
doi: 10.1016/j.wneu.2023.06.100
pubmed: 37390903
Ong K, Rizzuto M, Makarenko S (2023) Location pattern of recurrence of fully resected grade 1 meningiomas. Acta Neurochir (Wien) 165:2865–2871. https://doi.org/10.1007/s00701-023-05758-5
doi: 10.1007/s00701-023-05758-5
pubmed: 37620597